The transcription factor FoxO1 contributes to the metabolic adaptation to fasting by suppressing muscle oxidation of glucose, sparing it for glucosedependent tissues. Previously, we reported that FoxO1 activation in C 2 C 12 muscle cells recruits the fatty acid translocase CD36 to the plasma membrane and increases fatty acid uptake and oxidation. This, together with FoxO1 induction of lipoprotein lipase would promote the reliance on fatty acid utilization characteristic of the fasted muscle. Here, we show that CD36-mediated fatty acid uptake, in turn, upregulates protein levels and activity of FoxO1 as well as its target PDK4, the negative regulator of glucose oxidation. 
The transcription factor FoxO1 contributes to the metabolic adaptation to fasting by suppressing muscle oxidation of glucose, sparing it for glucosedependent tissues. Previously, we reported that FoxO1 activation in C 2 C 12 muscle cells recruits the fatty acid translocase CD36 to the plasma membrane and increases fatty acid uptake and oxidation. This, together with FoxO1 induction of lipoprotein lipase would promote the reliance on fatty acid utilization characteristic of the fasted muscle. Here, we show that CD36-mediated fatty acid uptake, in turn, upregulates protein levels and activity of FoxO1 as well as its target PDK4, the negative regulator of glucose oxidation. However, excess FA or diminished FA oxidation can lead to chronic accumulation of metabolites that impair insulin responsiveness of glucose utilization (1, 2) . Several reports have implicated high sarcolemmal levels of the FA translocase CD36 and persistently increased FA uptake in muscle insulin resistance (3) (4) (5) (6) . CD36 facilitates a large fraction of FA uptake by muscle (7) impacting glucose metabolism and insulin sensitivity (3, 8, 9) . Muscle CD36 protein levels are modulated by insulin, leptin, resistin, contraction, obesity and diabetes (3, 10) . In addition, CD36 is induced by the PPAR transcription factors (11, 12) which function as nutrient sensors and metabolic regulators (13, 14) . CD36-facilitated FA flux may in turn be a part of a feedback loop activating the PPARs; CD36 deficiency reverses myocardial lipotoxicity and functional impairments of the heart caused by PPARα overexpression (15) . CD36 expression is also important for PPARγ activation by dietary fat in adipose tissue (16) .
Optimal functioning and insulin responsiveness of muscle are linked to its ability to adjust fuel preference, suppressing glucose utilization, with more reliance on FA during nutrient shortage, and rapidly reversing these changes with feeding. The fasting/feeding adaptation is impaired in obesity and diabetes, described as diseases of metabolic inflexibility (17) (18) (19) . Several pathways contribute to the fasting/feeding response, notably those involving the PPARs and the AMP activated protein kinase (AMPK). The major PPAR isoform in muscle, PPARδ/β regulates FA catabolism and plays a central role in the adaptation to fasting (20) . AMPK on the other hand is activated by an increase in the AMP/ATP ratio, a sensitive indicator of cellular energy, and functions to restore ATP levels by enhancing oxidation of glucose and FA (21) . AMPK activation is especially important for the exercising muscle.
Recent evidence supports involvement of the transcription factor FoxO1 in regulating the adaptive metabolism of muscle. FoxO1 is activated by nutrient shortage and inhibited by insulin/growth factor signaling (22, 23) . Inhibition of FoxO1 activity mediates many effects of insulin on gene expression (24) (25) (26) . Fasting activates muscle FoxO1 contributing to induction of the pyruvate dehydrogenase kinase 4 (PDK4) (27) which then phosphorylates and inactivates pyruvate dehydrogenase (PDH) (28) . This inhibits pyruvate transition to acetyl-CoA and glucose oxidation. While PDH is acutely inhibited by FA oxidation products (high NADH/NAD+ and acetyl-CoA/CoA), chronically it is inactivated by PDK4. In addition to fasting, muscle PDK4 is increased by high fat diets (29) , diabetes and obesity suggesting it is a "lipid status" PDK isoform that facilitates FA oxidation (30) .
As FoxO1 induces PDK4 to suppress glucose oxidation, it also acts to increase sarcolemmal content of CD36 enhancing FA uptake and oxidation (31) . FoxO1 also suppresses expression of acyl-CoA carboxylase (ACC) which reduces levels of the FA oxidation inhibitor malonyl-CoA. Thus FoxO1 contributes to regulating muscle glucose and FA preference during fastingfeeding. Many pathways integrate feedback loops that optimize long term regulation (32-34) so we asked whether regulation of muscle FoxO1 and PDK4 was in turn responsive to CD36 function. This would be consistent with the reportedly high levels of CD36 (5, 35, 36) and PDK4 in diabetic muscle (29) . We examined how CD36 overexpression or knockdown impact FoxO1 level, ability to induce PDK4 and the muscle adaptation to fasting. Using in vitro and in vivo systems where expression of CD36, FoxO1 and PPARδ/β was manipulated, we document that CD36-facilitated FA uptake via regulating PPARδ/β and FoxO1 positively reinforces muscle FA utilization. This provides a potential mechanism by which FA uptake can chronically alter muscle bioenergetics.
EXPERIMENTAL PROCEDURES
Mouse models: CD36 null (37) mice and mice with muscle targeted CD36 overexpression (MCK-CD36) (9) (overexpressing CD36 in skeletal and heart muscles) were crossed five times to the C57Bl/6 background. PPARδ/β null (38) 
RESULTS

Long chain FAs upregulate FoxO1
expression in muscle cells -Excessive FA influx inhibits glucose utilization in muscle and contributes to the development of insulin resistance. We determined the effects of oleic acid on muscle glucose oxidation in C 2 C 12 myoblasts. Figure 1A shows that a 16 hr incubation with 400µM oleic acid markedly reduces glucose oxidation. We asked whether this effect correlates with induction or activation of known negative regulators of muscle glucose oxidation such as FoxO1.
Western blot analysis of C 2 C 12 cell lysates reveals increased total FoxO1 protein in cells receiving FA as compared to controls (Fig.  1B) . Constitutively active FoxO1 inhibits myoblast differentiation and FoxO1 ablation in skeletal muscle in vivo shifts fiber type distribution towards less of the slow twitch oxidative phenotype (44) . However, the effect of FA treatment on FoxO1 that we describe did not reflect altered myoblast differentiation. FA induction of FoxO1 was observed in myotubes ( Fig. 1B) and FA exposure for 16h did not alter expression of genes associated with myotube differentiation (data not shown) or myotube morphology. A corresponding hypo-phosphorylation (at Ser 256) of FoxO1 protein was detected in both myotubes and myoblasts suggesting FoxO1 activation (Fig. 1B) . As FoxO1 inhibitory phosphorylation at ser256 is typically mediated by activated AKT (22), we determined AKT status by assaying total and p-Ser(473) AKT protein levels. A marked reduction in phosphorylation at Ser(473) was observed ( Fig.1C) , consistent with the decrease in p-FoxO1 with no detectable difference in total AKT (Fig.1C ) or p-AKT(T308) levels (data not shown). Next, we investigated the involvement of AKT in the induction of total FoxO1 levels and examined whether they are altered by inhibition of the PI3 kinase pathway. It has been reported that in the presence of PI3Kinase inhibitors like Wortmannin, growth factors or insulin fail to affect total FoxO1 protein expression (23) . Myoblasts were treated with FA, in the presence or absence of Wortmaninn. As shown in Figure 1D , Wortmaninn reduces pFoxO1 levels as expected, but has no effects on total FoxO1 expression. Same results were obtained with another PI3Kinase inhibitor LY294002 (data not shown). Apparently, FA induced FoxO1 protein accumulation is not inhibited by compromising PI3Kinase signaling. We asked if the FA effect involved the proteosomal system with possible alteration in FoxO1 protein stability. Myoblasts were incubated in the presence or absence of LLnL, a potent proteosome inhibitor. As shown in Figure 1E , LLnL treatment and inhibition of proteosomal degradation mechanisms were sufficient to induce accumulation of p53, a proteosomal target. However, no alteration in FoxO1 protein expression was observed. Same results were obtained in a similar time course analysis in the presence of OA (data not shown). Collectively, our data indicate that oleic acid triggers the induction of total FoxO1 protein expression concomitant with a decrease in cellular glucose oxidation. The FA upregulation of total FoxO1 does not seem to involve the PI3Kinase pathway or proteosome mediated proteolysis. Effect of CD36 on FoxO1 level and activation -Fatty acid transfer into muscle in vivo is facilitated in large part by the membrane protein CD36 (7, 45) . Previously, we reported that enforced expression of CD36 in C 2 C 12 muscle cells increases FA uptake and oxidation (46) . We examined the effects of CD36 overexpression in these cells on FoxO1 levels. Figure 2A shows robust induction of FoxO1 protein with CD36 overexpressing. In vivo relevance was shown by the observation that transgenic mice (MCK-CD36) with muscle-specific CD36 overexpression had higher FoxO1 mRNA (Fig. 2B) . To determine the specific contribution of CD36, we generated a C 2 C 12 cell line stably expressing a CD36 RNAi construct (shCD36) and examined if CD36-loss-of-function can alter FoxO1 expression. Figure 2C shows that shCD36 expression resulted in marked knockdown of CD36 protein and decreased FA uptake (Fig. 2D) . Importantly, these effects were associated with robust downmodulation of FoxO1 protein.
An increase in glucose oxidation was also measured in shCD36-expressing cells (Fig.  2E) , consistent with the reduction in FoxO1 level and activity. Thus enforced expression of CD36 or its knockdown significantly induce or reduce FoxO1 expression, respectively. By influencing FoxO1 content, muscle CD36 expression, would contribute to long term regulation of muscle glucose oxidation.
Contribution of CD36 to Fasting Induction of FoxO1 and PDK4 -Short-term fasting in
muscle is characterized by reduced glucose utilization and by increased reliance on FA (17) . FoxO1 expression in muscle is enhanced by fasting (27) and FoxO1 activation in muscle cells increases membrane CD36 content and promotes FA uptake and oxidation (31) . We examined the adaptation to fasting and the contribution of CD36 in several relevant mice models. As shown in Figure 3A , a 16h overnight fast of WT mice is associated with a three-fold increase in muscle membrane CD36 content. Furthermore, as shown in Figure 3B fasting 3B ). Of note, basal glucose utilization was similar in the fed states in WT and CD36-null hearts and diaphragms, underscoring perhaps the more significant role for CD36 under states of elevated FA flux such as fasting. FoxO1 levels were examined and as shown in Figure 3C , FoxO1 protein expression is induced in the WT muscle (diaphragm) with fasting while this induction is blunted in age-and gender-matched CD36-deficient muscle. Similar effects, albeit more modest, are detected in heart tissues ( Fig.  3D) . Analysis of FoxO1 mRNA also reveals diminished induction with fasting in CD36-null muscle as compared to WT (Fig. 3E ). Importantly and in parallel with the changes in FoxO1 levels, induction of mRNA for PDK4, also induced with fasting (27) , was markedly blunted with CD36 loss (Fig. 3F) .
The role for CD36 in FoxO1 regulation in vivo was confirmed in another mouse model of altered CD36 expression in muscle, the double transgenic MKR-CD36. The MKR mouse has impaired IGF and insulin signaling in muscle as a result of muscle targeted expression of a dominant negative IGF receptor that hybridizes with both the IGF and insulin receptors (47) . The mouse exhibits reduced IGF and insulin stimulated glucose uptake in muscle and global insulin resistance. This mouse was also shown to have reduced muscle FA oxidation with enhanced accumulation of intramuscular triglycerides.
Muscle targeted CD36 overexpression in the MKR enhanced FA oxidation, reduced muscle lipid accumulation and was associated with a reversal of the diabetes (47) . To determine whether some of the defects in muscle FA metabolism in the MKR mouse may reflect an abnormal CD36-FoxO1 interaction, we examined muscle FoxO1 levels in MKR and MKR/CD36 mice. As shown in Figure 3G , FoxO1 and PDK4 protein levels were very low in the MKR muscle (lanes 1, 2) and were induced by CD36 expression (compare lanes 1, 2 to 5, 6) to levels comparable to those observed with fasting. Thus expression of CD36 was sufficient to induce FoxO1 and PDK4 in presence of compromised PI3Kinase signaling. This is consistent with our findings (Fig. 1 ) that FA induction of total FoxO1 protein is not altered by inhibiting PI3Kinase. The findings that CD36 loss attenuates fasting-induction of FoxO1 and PDK4 suggest that CD36 function is required for full induction of these proteins independent of the PI3 kinase pathway.
Kinetics for FA induction of FoxO1 and PDK4 -We and others reported that FoxO1 is sufficient to induce PDK4 (31) (27) . Binding of FoxO1 to the PDK4 promoter was suggested in C 2 C 12 cells (27) . To gain further insight into the FoxO1 regulation of PDK4, C 2 C 12 cells expressing exogenous FoxO1 fused to a modified estrogen receptor (FoxO1:ER) were used. In this cell system, the FoxO1 protein is relocated to the nucleus by tamoxifen (OHT) treatment (31) . We tested whether induction of PDK4 mRNA is altered in presence of Cycloheximide (CHX), an inhibitor of protein biosynthesis that blocks translational elongation. If PDK4 induction is a direct result of FoxO1 transcriptional activity, it will not be affected by CHX in this system. C 2 C 12 myoblasts stably expressing FoxO1:ER were treated with OHT for 8 hours in presence or absence of CHX. As shown in Figure 4A , PDK4 mRNA was induced by FoxO1 activation, as previously described (31) but this induction was prevented by CHX.
Apparently, activation of the FoxO1:ER is not sufficient to induce PDK4 in absence of de novo protein synthesis supporting requirement of additional factors and indirect transcriptional activation.
To further understand how FAs regulate the interaction of FoxO1 and PDK4 in muscle cells, we determined the changes in mRNA and protein expression for FoxO1 and PDK4 as a function of time following FA treatment. We first confirmed that PDK4, like FoxO1, is induced in response to FA (Fig.  4B) . Next, we analyzed the time course for this induction. Figure 4C shows that PDK4 mRNA is rapidly induced preceding that of FoxO1. Similar patterns were obtained for protein induction (Figure 4D and E). Collectively, these data support the interpretation that while FoxO1 can induce PDK4, under conditions of FA flux, FoxO1 and PDK4 are induced separately. Of note, JNK kinase which is potently activated by FA (48) and is implicated in acutely activating FoxO1(49) was quickly phosphorylated (activated) in these cells with no change in total JNK levels (data not shown). JNK phosphorylation is consistent with the effects of FA on p-AKT(Ser 473) (Fig. 1) as JNK modulates AKT activity and reduces p-AKT(Ser 473) levels (49) .
PPARδ/β contributes to FA regulation of FoxO1 in vivo -Free FA and their derivatives are activating ligands for the PPAR transcription factors (50, 51) . Recent data in heart (15) and adipose tissue (16) suggest that CD36 facilitated FA uptake is linked to PPAR activation. PPARδ/β expression in skeletal muscle is high, favoring oxidative fibers (52, 53) and this isoform has been implicated in regulating FA oxidation and in muscle adaptation to fasting (54) . Importantly, a new report showed that the PPARδ/β isoform regulates PDK4 expression via a direct transcriptional mechanism (55). In addition, the PPARδ/β targets ADRP and UCP2 were elevated early after FA addition to C 2 C 12 cells as shown in Figure 4F . Similar early induction was also observed for the PPARδ/β target UCP3 (data not shown). As such, we asked whether PPARδ/β could be involved in induction of FoxO1 expression by CD36-mediated FA flux. We determined the expression of Adipophilin (ADRP) and UCP-3 in the feeding/fasting cycle. As shown in Figure 5A , expression of these targets was responsive to fasting and this response was significantly diminished in CD36-deficient as compared to WT muscle. Expression of ADRP and UCP-3 was similarly blunted in PPARδ/β-deficient muscle, as expected. In contrast, expression of these PPARδ/β targets was increased in skeletal muscle from transgenic MCK-CD36 mice where muscle CD36 expression is enhanced (data not show), and where FoxO1 is induced by fasting (data not shown). Apparently, conditions of elevated FA flux or CD36 overexpression correlate with enhanced PPARδ/β activity as reflected by target genes while CD36 deficiency is associated with opposite changes. Therefore, we determined the effect of PPARδ/β loss on FoxO1 in vivo. A reduction of FoxO1 induction would be expected if PPARδ/β is required for FoxO1 expression. As shown in Figure 5B , homozygous loss of PPARδ/β compromises myocardial expression of FoxO1 and its induction with fasting. Fasting induction of FoxO1 was also blunted in diaphragms of PPARδ/β-deficient mice compared to WT (Fig. 5C ) and similar effects were also observed with CD36-deficiency (Fig. 5C) . Induction of PDK4 expression was markedly suppressed in tissues deficient in either CD36 or PPARδ/β (Fig. 5D) . In summary, loss of PPARδ/β, like that of CD36, suppresses induction of FoxO1 and PDK4 in response to fasting. The data suggest that CD36 facilitated FA activation of PPARδ/β is required for fasting induction of FoxO1 and PDK4.
PPARδ/β is sufficient to induce FoxO1 and inhibits glucose oxidation -We confirmed that the PPARδ/β targets are induced in C 2 C 12 cells where FoxO1 and PDK4 are elevated in response to FA treatment. As shown in Figure  6 , oleic acid induced expression of the PPARδ/β targets UCP2, UCP3 and ADRP in C 2 C 12 myoblasts and myotubes ( Fig. 6A and 6B, respectively). We then stably introduced PPARδ/β into C 2 C 12 myoblasts and asked whether this would be associated with FoxO1 induction. PPARδ/β over-expression was sufficient to robustly induce FoxO1 (Fig. 6C,  compare lanes 1 and 3 or lanes 2 and 4) . (Fig. 6E , compare lane 1 to 3 or 2 to 4). Taken together, muscle FoxO1 expression is regulated by PPARδ/β, and this could mediate, at least in part, the effect of CD36-facilitated FA uptake.
PPARδ/β regulates FoxO1 through a transcriptional mechanism -The mechanism of PPARδ/β regulation of FoxO1 was examined further. To determine whether the FoxO1 promoter contains PPRE binding sites the MATCH program associated with the TRANSFAC database of cis-regulatory motifs (56) was used. This unbiased approach identifies transcription factor binding sites on the basis of position weight matrices (PWM) constructed from previously characterized binding sites, and assigns scores for similarity between a candidate site and the PWM. As show in Figure 7A and B, PPAR response elements, including at least one predicted PPRE site were identified in the FoxO1 promoter. The genomic fragment containing the predicted PPARδ/β sites (sequences +732 to -237 relative to the transcriptional start site TSS) were cloned into a luciferase reporter plasmid (FoxO1-luc) which was cotransfected into C 2 C 12 myoblasts with either an empty vector control or a PPARδ/β expression plasmid and a normalization control. As shown in Figure 7C , PPARδ/β induces significant transactivation of the FoxO1-Luc reporter. Co-transfection in the presence or absence of the PPARδ/β agonist, GW0742 is shown in Figure 7D . As expected, the FoxO1 promoter was responsive to increasing doses of GW0742 (0, 40 and 120 nM). Similar results were obtained when we measured FoxO1 transactivation as a function of time (0, 6 and 16 hrs, Fig. 7E ) in the presence of PPARδ/β agonist. Finally, and as expected, cells expressing a DN PPARδ/β failed to respond to agonist stimulation (Fig.  7E) . Together, the data support existence of a transcriptional mechanism for PPARδ/β regulation of FoxO1 likely acting in concert with that of PPARδ/β on PDK4 (55).
DISCUSSION
Muscle tissue accounts for one third of the resting metabolic rate and for a major fraction of insulin-stimulated glucose uptake. Thus its flexibility with respect to fuel preference is crucial for glucose homeostasis. In insulin resistance, muscle adaptation to fasting and feeding appears dysfunctional with features of the fasted state such as enhanced FA utilization persisting into the fed state (19) . A better understanding of the molecular mechanisms mediating normal muscle adaptation may provide insight into the etiology of metabolic diseases. This study shows that CD36 facilitated FA uptake modulates PPARδ/β and FoxO1 function to reinforce muscle reliance on FA and the adaptation to fasting. First, CD36 overexpression or knockdown in vitro correlates with FoxO1 and PDK4. Second, CD36 deficiency or overexpression, in vivo, has opposite effects on fasting-induction of FoxO1 and PDK4, which are paralleled with altered substrate utilization. Third, regulatory effects of CD36-FA uptake on FoxO1 and PDK4 involve PPARδ/β as shown by its overexpression or knockdown in vitro and by its deletion in vivo. Fourth, FA activated PPARδ/β directly induces FoxO1 expression. The data suggest that CD36/FA uptake in fasting upregulates PPARδ/β activity, levels at Washington University on February 29, 2008 www.jbc.org Downloaded from and activity of FoxO1 and PDK4. As a result it contributes to determining muscle fuel preference and ability to adapt to metabolic stress.
The FoxO1 transcription factor has been implicated in regulating various aspects of cellular metabolism (57) (58) (59) .
In the liver FoxO1 suppresses glycolysis and lipogenesis while increasing gluconeogenesis (60, 61) . In muscle, fasting upregulates FoxO1, which contributes to induction of PDK4 inhibiting glucose oxidation (27) . FoxO1 activation also recruits CD36 to the sarcolemma (31) and induces lipoprotein lipase (62) to coordinately increase FA uptake. Regulation of FoxO1 appears to integrate several signaling inputs. Post-translational modifications that acutely alter the FoxO1 proteins are the most understood events (63). Among these the role of JNK (activation) and AKT (inhibition) in FoxO1 regulation are well documented (23) . However, the mechanisms that may promote increased steady state FoxO1 levels, as documented with fasting or diabetes remain poorly defined. One of the findings of this study is that FoxO1 level is sensitive to increased CD36 facilitated FA flux. As FoxO1 promotes enrichment of membrane CD36, the ensuing enhancement in FA uptake is likely maintained via positive feedback-regulation of both FoxO1 activity (via AKT inactivation and JNK activation) and expression (via PPARδ/β). Thus it is conceivable that conditions that chronically change muscle CD36 content would alter the adaptive response of FoxO1 and PDK4 to metabolic challenges, which may relate to how FA induce muscle insulin resistance. In this context, the CD36 null mouse where FA uptake into muscle is impaired has blunted fasting induction of muscle FoxO1 and PDK4 ( Fig. 3 and 5 ) and this is associated with enhanced insulin sensitivity and glucose uptake in this tissue (64) . On the other hand, the mouse with muscle targeted CD36 overexpression (MCK-CD36), with higher muscle FoxO1 ( Figure 2B ) has features of insulin resistance that include high glucose and insulin levels (9) . Thus the increased FoxO1 and PDK4 expression in obesity and diabetes (28, 29) may reflect in part the high sarcolemmal CD36 in these conditions (3) and possibly could be reversed by CD36 downregulation.
Our findings indicate that PPARδ/β, a FA activated nuclear receptor, induces transcription of FoxO1 and loss-of-function experiments in vitro and in vivo (PPARδ/β-null mouse) demonstrate its pivotal role in FoxO1 regulation. Recent evidence show that PDK4 is also a direct target of PPARδ/β (55) further supporting the primary role of this isoform in regulating muscle oxidative metabolism. Activation of PPARδ/β in muscle induces a fasting-like phenotype characterized by increased FA oxidation and suppressed glucose oxidation (65) . This phenotype is similar to that induced by FoxO1, which together with our data suggests that some PPARδ/β effects in muscle may be mediated via FoxO1. This would be consistent with the report that PPARδ/β agonists initiate a muscle atrophy program (66) that is regulated by the PI3K/AKT/FoxO1 pathway (67) . It is important to emphasize that findings of this study, especially results described in Figure 4 , favor the interpretation that PDK4 expression under conditions of FA flux is not FoxO1 dependent. Given the transcriptional regulation of both PDK4 and FoxO1 by PPARδ/β, these genes are likely regulated independently by this PPAR as further depicted in the model in Figure 8 .
Conceivably, some metabolic effects of CD36 facilitated FA flux in the fasted muscle may involve the AMPK pathway which contributes to adaptive regulation of muscle glucose and FA oxidation. We did not detect changes in levels of phsophorylated AMPK or ACC in response to CD36 deletion (data not shown). However, this does not rule out a role for AMPK since FA flux may alter the interaction between PPARδ/β and AMPK (68), which was not examined. FA effects on the interaction of PPARδ/β and PGC-1alpha, which plays a key role in regulating mitochondrial biogenesis and oxidative capacity (13, 69, 70) was also not considered and will need to be examined. Our data, which focused on PPARδ/β do not rule out at Washington University on February 29, 2008 www.jbc.org Downloaded from contribution of PPARα to the observed effects of FA and there is evidence for significant redundancy in the regulatory effects of the two isoforms in muscle (71) . Of note, while fasting induction of PDK4 is unaltered in skeletal muscle or slightly reduced in heart from PPARα null mice (71) , it is markedly blunted in both tissues of the PPARδ/β null mouse (Fig. 5) . This suggests that PPARδ/β is more directly involved in regulating muscle fuel preference in response to fasting.
In conclusion, the functional interplay between CD36, a major FA uptake protein in muscle, PPARδ/β, FoxO1 and PDK4, key modulators of glucose and FA metabolism provides a framework for long term regulation of muscle fuel preference. Dysfunction in either of these factors by virtue of their interdependency would lead to an abnormal metabolic profile and alter adaptability of the tissue to energy challenges. Suppressing CD36 expression and hence reducing FA flux could improve metabolism of insulin resistant muscle by restoring regulation of PDK4 and ability to oxidize glucose. Although this has not been directly tested, it would be consistent with the phenotypes of the CD36-null (64) or the transgenic MCK-CD36 mice (9) . However, in certain contexts, enforced CD36 expression may have beneficial effects in activating PPARδ/β to promote FA uptake and oxidation, as in the MKR muscle (47) . Activation of PPARδ/β can improve muscle FA oxidation, the plasma lipid profile and has insulin sensitizing effects (72) . The fact that CD36 overexpression is beneficial in the context of absent insulin and IGF-1 signaling (MKR) suggests that glucose metabolism and insulin action may contribute to the long term negative effects of excess FA flux by inhibiting FA oxidation (73) (74) (75) . The ensuing imbalance between FA uptake and oxidation would predispose to insulin resistance and is consistent with the findings that insulinresistant muscle exhibits impaired FA oxidation (76) (77) (78) . Thus, therapies targeting CD36 or PPARδ/β would have to carefully consider the context involved. (31) . (E) Glucose oxidation for C 2 C 12 myoblasts shown in C as described (31) . Data are means ± SEM (n=3). P values <0.05 are considered significant.
Fig. 3: CD36 contributes to regulation of muscle FoxO1 and PDK4 levels in fasting.
(A) CD36 protein levels in membrane fractions obtained from heart of fed and fasted (16h) mice. (B) Glucose uptake in heart and diaphragm of WT and CD36 -/-mice with fasting (16h). Uptake was determined by 18 FDG uptake (7). FoxO1 protein in total lysate of (C) diaphragm and (D) heart muscles from fed and fasted (16 h) WT and CD36 -/-mice α-tubulin was used as loading control. Basal FoxO1 protein levels in muscles from fed CD36 -/-are not reduced compared to fed WT (data not shown) consistent with basal glucose utilization (part 3B) (E) Fold induction with fasting (16h) of FoxO1 and (F) PDK4 mRNA, determined by Q-PCR in the indicated tissues from WT and CD36 -/-mice. In all panels, values are means (n=3) ± SEM. Statistical significance determined by Student's t-test, P values <0.05 are significant. (G) FoxO1 and PDK4 protein in total tissue lysate of heart muscle from fed and fasted MKR and MKR-CD36 mice. -/-and PPARδ/β -/-mice. mRNA determined by Q-PCR is expressed as fold change with fasting ± SEM (n=3). P<0.05 is significant. 
